Positive Federal Legislation Could Lead to Exponential Growth in Marijuana and CBD Industry

LAS VEGAS, May 2, 2018 /PRNewswire/ --

FN Media Group Presents Microcapspeculators.com News Commentary 

USA Today recently reported that "America's fast-growing marijuana industry appears poised for supercharged growth after winning what cannabis entrepreneurs see as approval from the current administration to forge ahead. "Across the nation, risk-takers have poured billions of dollars into the industry. Mentioned in today's commentary includes: NightFood Holdings, Inc. (OTC: NGTF), Kush Bottles, Inc. (OTC: KSHB), AbbVie, Inc. (NYSE: ABBV), Innovative Industrial Properties, Inc. (NYSE: IIPR), and Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE).

They've built - largely unseen - a powerful network of businesses poised to take advantage of a more favorable federal climate. That industry has already woven itself into the fabric of the states where pot is legal, providing tens of thousands of jobs and generating billions of dollars in new tax revenues.

Experts say those numbers are now likely to rise rapidly thanks to the president's promised hands-off approach and support of some sort of federal solution.

"Every day we wake up and build this industry. And every day we do that, it's a little harder to shut it down," said Daniel Yi, a spokesman for the California-based marijuana powerhouse MedMen.

There's no denying America's love affair with marijuana is accelerating across the nation as voters loosen laws and grow increasingly comfortable with a drug that has been forbidden for generations. Today, more than 60% of Americans believe marijuana should be legal, double its popularity in 2000, according to a January 2018 poll by the Pew Research Center. That comes against a backdrop of contrasting studies that have offered little insight into how legalization is impacting youth use, stoned driving and border-state black markets."

Now let's take a look at a few companies that could benefit from positive marijuana legislation: NightFood Holdings, Inc. (OTC: NGTF), Kush Bottles, Inc. (OTCQB: KSHB), AbbVie, Inc. (NYSE: ABBV), Innovative Industrial Properties, Inc. (NYSE: IIPR), and Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE).

NightFood Holdings, Inc. (OTC: NGTF)

Market Cap: $16.99M, current share price: $.4195 

NightFood Holdings, Inc. (NGTF), a brand development company pioneering the projected billion-dollar nighttime nutrition category and developing unique products in the marijuana/cannabis/CBD related snack space, recently announced that the Company has entered into its first licensing agreement as part of their plan to build a national brand of popular snacks under the powerful Half-Baked™ brand trademark.

An initial production run of Half-Baked™ cannabis infused cookies is expected to be completed shortly, and product should be on shelf during the month of May 2018.  

Kush Bottles, Inc. (OTCQB: KSHB)

Market Cap: $362,664,878, current share price: $5.65 

Kush Bottles, Inc. a leading provider of packaging, supplies, vaporizers, accessories and branding solutions for the regulated cannabis industry, announced yesterday that it has partnered with MainStem, a technology-based ancillary product distribution company for the regulated cannabis industry, to be the inaugural partner for MainStem's Vendor Program (MVP).  The company's security is up considerably this year, and back in February hit a 52 week high of $8.51.  

AbbVie, Inc. (NYSE: ABBV)

Market Cap: $161.9B, current share price: $102.07 

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Their Marinol drug is FDA-approved for the treatment of nausea in patients undergoing chemotherapy and is also prescribed to AIDS patients suffering from loss of appetite. The drug is made of a synthetic form of THC and is delivered as an oral capsule.

ABBV recently submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for risankizumab, an investigational interleukin-23 (IL-23) inhibitor, being evaluated for the treatment of patients with moderate to severe plaque psoriasis.

Cara Therapeutics, Inc.  

Market Cap: $423.46M, current share price: $12.92 

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company, focusing on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. Cara is developing lead molecules that selectively modulate peripheral CB receptors without targeting CNS cannabinoid receptors. Peripheral CB receptor modulators will be initially developed as a novel therapeutic approach for neuropathic and inflammatory pain, a condition currently without consistently effective therapies. Cara's most advanced CB compound, CR701, is currently in preclinical development.

CARA just released a transcript of their Q1 earnings call: https://finance.yahoo.com/news/edited-transcript-cara-earnings-conference-122442595.html

Innovative Industrial Properties, Inc. (NYSE: IIPR)

Innovative Industrial Properties, Inc. is the leading provider of creative real estate capital solutions to the medical cannabis industry.   Recently the company announced that it closed on the acquisition of a property located at 2000 Rosanna Avenue in Scranton, Pennsylvania, which comprises approximately 89,000 square feet of industrial space.  The purchase price of the property was approximately $5.8 million.  The company's security is only about 5% off of its 52 week high.  

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)

Market Cap: $141.17M, current share price: $10.41 

ZYNE, a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, is reporting new longer term open label clinical data today in the Emerging Science session of the 2018 Annual Meeting of the American Academy of Neurology (AAN) in Los Angeles, CA.

In a poster presentation entitled, "Transdermal Cannabidiol (CBD) Gel for the Treatment of Focal Epilepsy in Adults" (poster P4.468), Dr. John Messenheimer presents additional data from ongoing STAR 2 (Synthetic Transdermal CAnnabidiol for the TReatment of Epilepsy) 24-month open label extension study evaluating ZYN002 cannabidiol (CBD) transdermal gel in adult patients with focal seizures. The presentation includes data through twelve months of open label exposure to ZYN002.

Content Provided By: Microcap Speculators

Email: [email protected]

Phone: 1-702-720-6310

Website: http://microcapspeculators.com/

For Full Legal Disclaimer Click Here.

DISCLAIMER: Microcapspeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM,) and its online brand FinancialNewsMedia.com, is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks included herein by MS. FNM was not compensated by any public company mentioned herein to disseminate this press release on behalf of MS.

MS Disclosure:  Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.

Media Contact
FN Media Group LLC
e-mail:  [email protected]
(954)-345-0611

SOURCE Microcapspeculators.com